NAVB's logo.
Ticker Symbol: NAVB

Navidea Biopharmaceuticals Inc

$1.40 - 20-11-2024 4 p.m. ET

Exchange: NYSE MKT LLC Country: US Currency: USD Asset Type: Common Stock CIK:0000810509

Company Profile

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) is a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics. Navidea is developing multiple precision-targeted products based on its Manocept™ platform to enhance patient care by identifying the sites and pathways of disease and enable better diagnostic accuracy, clinical decision-making, and targeted treatment. Navidea's Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages. The Manocept platform serves as the molecular backbone of Tc99m tilmanocept, the first product developed and commercialized by Navidea based on the platform. Navidea's strategy is to deliver superior growth and shareholder return by bringing to market novel products and advancing the Company's pipeline through global partnering and commercialization efforts.

Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Standard Industrial Classification Code (SIC code): 2835
Address: 4995 Bradenton Ave Ste 240
CEO: Jed Latkin
Tags:
  • Health Technology
  • Biotechnology
  • Pharmaceuticals: Major
  • Manufacturing
  • Pharmaceutical Preparation Manufacturing

Pricing

Last Updated: October 3, 2023 03:00 PM EST
Previous Close: $0.08
Change: $0.00 ( -5.17%)
Days Range: $0.08 - $0.09
Beta: -
52wk. High: $0.06
52wk. Low: $0.02
Ytd. Change -61.83%
50 Day Moving Average: $0.04
200 Day Moving Average: $0.04
Shares Outstanding: 100084385

Valuation

Market Cap: 863.7M
PE Ratio: -0.45
EPS (TTM): -0.1911

Dividends

Dividend Per Share (TTM): -
Dividend Yield (TTM): 0.00%
Ex-Dividend Date: N/A